Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity
- 10 September 2022
- journal article
- review article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 67, 104172
Abstract
No abstract availableKeywords
This publication has 122 references indexed in Scilit:
- Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-TherapyPLOS ONE, 2013
- No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirusEuropean Journal of Epidemiology, 2013
- Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patientsMultiple Sclerosis Journal, 2009
- Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinationsActa Neurologica Scandinavica, 2009
- CNS demyelination and quadrivalent HPV vaccinationMultiple Sclerosis Journal, 2009
- Yellow Fever: Epidemiology and PreventionClinical Infectious Diseases, 2007
- Transverse myelitis after measles and rubella vaccinationJournal of Paediatrics and Child Health, 2004
- Risk factors of multiple sclerosis: a case-control studyNeurological Sciences, 2003
- Hepatitis B vaccinesJournal of Hepatology, 2003
- Vaccinations and the Risk of Relapse in Multiple SclerosisNew England Journal of Medicine, 2001